Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NODAGA-E[c(RGDyK)]2 PET in Myocardial Infarction
NCT03445884Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Feb 2018
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by Rigshospitalet. Primary endpoint: Evaluation of myocardial angiogenesis via 68Ga-NODAGA-E[c(RGDyK)]2 uptake. Started Feb 2018; status: completed.
Beyond the preview
Go deeper on NCT03445884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445884.